Circulating Cell-Free Tumor DNA Market Poised to Grow Substantially due to Rising Adoption for Liquid Biopsy Applications
Circulating cell-free tumor DNA (ctDNA) refers to fragments of tumor DNA that are released into the bloodstream from cancer cells as they die. These ctDNA fragments carry genetic alterations that are characteristic of the tumor. The analysis of ctDNA provides a noninvasive method known as liquid biopsy for the detection and monitoring of cancers. It helps physicians learn about a patient’s tumor without needing tissue biopsy. Researchers are evaluating liquid biopsy's ability to detect cancer recurrence earlier than standard imaging tests. The global circulating cell-free tumor DNA Market is estimated to be valued at US$ 6.1 Bn in 2023 and is expected to exhibit a CAGR of 6.4% over the forecast period 2023 to 2030, as highlighted in a new report published by Coherent Market Insights.
Market Dynamics:
As per the provided data, the key driver incorporated in the heading is 'Rising adoption for Liquid Biopsy Applications'. Liquid biopsy uses ctDNA in blood for non-invasive cancer screening and monitoring; it helps avoid repeated invasive tissue biopsies thus drives patient preference. The rising adoption of liquid biopsy for early cancer detection also helps commence treatment at early stages, improving clinical outcomes. Moreover, liquid biopsy aids in tracking tumor mutations during and after therapy to ascertain treatment response or early signs of relapse compared to standard imaging. This driver has led to growing demand for ctDNA in clinical trials and research activities, thereby fueling the circulating cell-free tumor DNA market growth over the forecast period.
SWOT Analysis
Strength: Circulating Cell-Free Tumor DNA provides noninvasive testing approach for cancer screening and management. It can detect and analyze molecular markers in blood samples without surgery. Also, it allows longitudinal monitoring of cancer during and after treatment in a simple blood draw.
Weakness: Circulating Cell-Free Tumor DNA technology is still at an early stage of research and development and requires extensive validation. Due to complex nature of analysis, it demands skillful technical expertise and sophisticated infrastructure that may limit its wide applications.
Opportunity: Rising burden of cancer cases worldwide presents lucrative prospects for development and adoption of noninvasive diagnostic tests. Circulating Cell-Free Tumor DNA can transform cancer screening approach if proven effective for early detection of various cancer types. Growing funding for cancer research may encourage innovations in this area.
Threats: Stringent regulatory processes could delay market approval and commercialization of Circulating Cell-Free Tumor DNA tests. Ethical issues involving handling of patients' blood samples and privacy of genetic data need to be addressed carefully. Established cancer screening methods may limit faster uptake of new technology initially.
Key Takeaways
The global Circulating Cell-Free Tumor DNA Market Growth is expected to witness high growth over the forecast period of 2023 to 2030. It is projected that the market will grow at a CAGR of 6.4% during this period and reach a size of US$ 6.1 Bn by 2024.
Regional analysis: North America currently dominates the global market due to advancements in diagnostic technologies and availability of reimbursement. However, Asia Pacific region is likely to offer lucrative opportunities owing to increasing healthcare investments, rising cancer burden, and growing focus on diagnostic innovations.
Key players: Key players operating in the Circulating Cell-Free Tumor DNA market are BASF SE, Perstorp Holding AB, Chemoxy International Ltd., and Merck Group. These players are focusing on new product launches, collaborations and geographic expansions to consolidate their market presence.
For more details on the report, Read- https://shoutingstars.com/pd-1-and-pd-l1-inhibitors-a-promising-cancer-immunotherapy
English
Arabic
Français
Español
Português
Deutsch
Dutch
Italiano
Russian
Romaian